Eukroma Cream for Effective Hyperpigmentation Treatment
| Product dosage: 20g | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $40.42 | $40.42 (0%) | 🛒 Add to cart |
| 2 | $32.68 | $80.84 $65.36 (19%) | 🛒 Add to cart |
| 3 | $24.37 | $121.26 $73.10 (40%) | 🛒 Add to cart |
| 4 | $20.43 | $161.68 $81.70 (49%) | 🛒 Add to cart |
| 5 | $17.89 | $202.10 $89.44 (56%) | 🛒 Add to cart |
| 6 | $16.77 | $242.52 $100.62 (59%) | 🛒 Add to cart |
| 7 | $15.11 | $282.94 $105.78 (63%) | 🛒 Add to cart |
| 8 | $14.08 | $323.36 $112.66 (65%) | 🛒 Add to cart |
| 9 | $13.57 | $363.78 $122.12 (66%) | 🛒 Add to cart |
| 10 | $12.99
Best per tube | $404.20 $129.86 (68%) | 🛒 Add to cart |
Eukroma Cream is a topical dermatological preparation containing Hydroquinone as its active pharmaceutical ingredient. It is a first-line therapeutic agent prescribed by dermatologists for the management of various forms of hyperpigmentation. This cream works by selectively inhibiting the enzyme tyrosinase, which is crucial in the melanin synthesis pathway within melanocytes. Its formulation is designed for targeted application, offering a clinically proven approach to lighten darkened areas of the skin such as melasma, age spots, and post-inflammatory hyperpigmentation. Professional medical supervision is strongly advised to ensure appropriate use and monitor treatment efficacy and safety.
Features
- Active Ingredient: Hydroquinone 2% w/w or 4% w/w
- Pharmaceutical Form: Topical cream emulsion
- Mechanism of Action: Competitive inhibition of tyrosinase enzyme
- Formulation: Often includes sunscreens and emollients for enhanced stability and skin protection
- Prescription Status: Available as a prescription-only medication in most regions
- Packaging: Typically supplied in airtight tubes of 15g or 30g to prevent oxidation and degradation
Benefits
- Clinically proven reduction in the appearance of melasma and chloasma
- Effective lightening of hyperpigmented lesions including age spots and freckles
- Helps achieve a more uniform skin tone and texture
- Minimizes the visibility of post-inflammatory hyperpigmentation from acne or injury
- Targeted action with minimal effect on surrounding normal skin when applied correctly
- Can be part of a combination therapy regimen for stubborn pigmentation under dermatological guidance
Common use
Eukroma Cream is primarily indicated for the treatment of hyperpigmentary disorders. Its most frequent applications include idiopathic melasma, which presents as symmetrical, blotchy, brownish facial pigmentation, often hormonally influenced. It is also prescribed for ephelides (freckles) and solar lentigines (age or liver spots) caused by cumulative sun exposure. Furthermore, it is utilized in managing post-inflammatory hyperpigmentation resulting from conditions like acne vulgaris, eczema, psoriasis, or skin trauma. Off-label uses may include the treatment of certain other dyschromias, but only under strict dermatological supervision due to the potent nature of the active compound.
Dosage and direction
Apply a thin film of Eukroma Cream to the affected area(s) twice daily, or as directed by a physician. Morning and evening applications are standard. The skin should be clean and dry before application. Use the fingertip to gently dab a small amount—a pea-sized quantity is often sufficient for the entire face. Rub in gently and thoroughly until absorbed. It is critical to avoid contact with eyes, eyelids, lips, mucous membranes, and normal surrounding skin to prevent irritation or unintended hypopigmentation. Treatment duration is typically limited; most regimens advise use for no more than 5 months continuously. Always follow the specific instructions provided by your prescribing dermatologist, as dosage may be adjusted based on individual response and tolerance.
Precautions
- For external use only. Do not apply on broken, inflamed, or irritated skin.
- A patch test is recommended prior to full application to check for sensitivity or allergic reaction.
- Sun avoidance and broad-spectrum sunscreen (SPF 30 or higher) are mandatory during treatment and for several weeks after discontinuation, as hydroquinone can increase photosensitivity.
- Discontinue use and consult a dermatologist immediately if excessive redness, peeling, discomfort, or blue-black discoloration (ochronosis) occurs.
- Not recommended for use in children or during pregnancy and lactation unless explicitly advised by a healthcare professional after risk-benefit analysis.
- Do not use under occlusive dressings unless specifically instructed by a physician.
Contraindications
Eukroma Cream is contraindicated in individuals with a known hypersensitivity to hydroquinone or any other component of the formulation. It should not be used by patients with a history of ochronosis, fish odor syndrome (trimethylaminuria), or glucose-6-phosphate dehydrogenase (G6PD) deficiency. Its use is also contraindicated in cases where the pigmentation is not epidermal-dermal in origin, such as melanoma or nevus of Ota. Concomitant use with other potent topical agents like benzoyl peroxide, hydrogen peroxide, or other resorcinol-containing products should be avoided due to risk of skin discoloration.
Possible side effect
Common side effects may include mild, transient erythema (redness), skin dryness, and slight burning or stinging upon application. These often subside with continued use. Less frequently, patients may experience more pronounced irritation, dermatitis, or allergic contact sensitization. Rare but serious adverse effects include exogenous ochronosis (blue-black pigmentation), which may be irreversible, and hypopigmentation of surrounding normal skin. There is a theoretical risk of carcinogenicity with long-term, high-dose use, though evidence in humans is inconclusive. Any unusual skin changes or persistent discomfort should be reported to a healthcare provider promptly.
Drug interaction
Concurrent use with other topical medications, especially those containing peroxides (e.g., benzoyl peroxide), resorcinol, or salicylic acid, may lead to skin darkening or increased irritation. Using retinoids, corticosteroids, or glycolic acid concurrently may enhance penetration and efficacy but also increase the risk of irritation; such combination therapy should only be undertaken under medical supervision. There are no well-documented systemic interactions, but caution is advised when using other photosensitizing agents.
Missed dose
If a dose is missed, apply it as soon as remembered. However, if it is nearly time for the next scheduled application, skip the missed dose and resume the regular dosing schedule. Do not apply a double dose to compensate for a missed one, as this may increase the risk of skin irritation or other adverse effects.
Overdose
Topical overdose is unlikely to cause systemic toxicity but can result in severe local skin reactions, including intense erythema, burning, scaling, and blistering. In case of accidental ingestion, seek immediate medical attention. Symptoms of oral overdose may include nausea, vomiting, tinnitus, dyspnea, cyanosis, convulsions, and collapse due to methemoglobinemia. Treatment is supportive and symptomatic.
Storage
Store Eukroma Cream at room temperature (15–30°C), in its original container, tightly closed and protected from light. Keep away from excessive heat and moisture. Do not freeze. Due to oxidation, the cream may darken over time; discard if it turns brownish. Keep out of reach of children and pets.
Disclaimer
This information is intended for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional, preferably a dermatologist, before starting, changing, or stopping any medication. Do not use this product without a valid prescription and appropriate diagnosis. The manufacturer and provider of this information disclaim any liability for adverse effects resulting from the use or misuse of this product.
Reviews
Clinical studies and dermatological practice consistently report Eukroma Cream as effective for epidermal hyperpigmentation when used as directed. In a 12-week randomized trial, over 70% of patients with moderate melasma showed significant lightening. Patient testimonials frequently note visible improvement in skin tone within 4–8 weeks, though results vary. Some users report mild dryness or irritation, emphasizing the need for moisturization and sun protection. Long-term satisfaction is high when treatment is supervised and combined with photoprotection measures.